Evidence map›Paper›PMID 37129566›Full record

ArticleBiomaterials science2023

Biomaterials-based immunomodulation enhances survival of murine vascularized composite allografts.

Sven D Sommerfeld, Xianyu Zhou, Joscelyn C Mejías, Byoung Chol Oh, David R Maestas, Georg J Furtmüller, Philippe A Laffont, Jennifer H Elisseeff, Gerald Brandacher

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomaterials science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Sven D SommerfeldTranslational Tissue Engineering Center, Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. jhe@jhu.edu.ORCID http://orcid.org/0000-0002-0376-1513
Xianyu ZhouDepartment of Plastic and Reconstructive Surgery, Vascularized Composite Allotransplantation (VCA) Laboratory, Johns Hopkins School of Medicine, Baltimore, MD, USA. brandacher@jhmi.edu.ORCID http://orcid.org/0000-0003-0959-0011
Joscelyn C MejíasTranslational Tissue Engineering Center, Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. jhe@jhu.edu.ORCID http://orcid.org/0000-0003-4397-9741
Byoung Chol OhDepartment of Plastic and Reconstructive Surgery, Vascularized Composite Allotransplantation (VCA) Laboratory, Johns Hopkins School of Medicine, Baltimore, MD, USA. brandacher@jhmi.edu.
David R MaestasTranslational Tissue Engineering Center, Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. jhe@jhu.edu.ORCID http://orcid.org/0000-0002-8207-1835
Georg J FurtmüllerDepartment of Plastic and Reconstructive Surgery, Vascularized Composite Allotransplantation (VCA) Laboratory, Johns Hopkins School of Medicine, Baltimore, MD, USA. brandacher@jhmi.edu.ORCID http://orcid.org/0000-0001-8286-0968
Philippe A LaffontTranslational Tissue Engineering Center, Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. jhe@jhu.edu.
Jennifer H ElisseeffTranslational Tissue Engineering Center, Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD, USA. jhe@jhu.edu.ORCID http://orcid.org/0000-0002-5066-1996
Gerald BrandacherDepartment of Plastic and Reconstructive Surgery, Vascularized Composite Allotransplantation (VCA) Laboratory, Johns Hopkins School of Medicine, Baltimore, MD, USA. brandacher@jhmi.edu.
Johns Hopkins University · USBloomberg (United States) · US

Funding

Biomaterials-directed regenerative immunotherapiesDP1AR076959 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI ELISSEEFF, JENNIFER H · 2019 to 2023
$5.7M
NIAMS NIH HHS DP1 AR076959
6 · The paper itself

Abstract

Vascularized composite allotransplantation (VCA) is a restorative option for patients suffering from severe tissue defects not amenable to conventional reconstruction. However, the toxicities associated with life-long multidrug immunosuppression to enable allograft survival and induce immune tolerance largely limit the broader application of VCA. Here, we investigate the potential of targeted immunomodulation using CTLA4-Ig combined with a biological porcine-derived extracellular matrix (ECM) scaffold that elicits a pro-regenerative Th2 response to promote allograft survival and regulate the inflammatory microenvironment in a stringent mouse orthotopic hind limb transplantation model (BALB/c to C57BL/6). The median allograft survival time (MST) increased significantly from 15.0 to 24.5 days (

Indexed as

Composite Tissue AllograftsAbataceptAnimalsImmunomodulationMiceMice, Inbred C57BLSwineTransplantation, HomologousAbatacept

Identifiers

PMID37129566
PMCPMC12503134
OpenAlexW4367668266

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.